

Jussi P Koivunen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/681746/publications.pdf>

Version: 2024-02-01

37
papers

1,602
citations

567281

15
h-index

345221

36
g-index

43
all docs

43
docs citations

43
times ranked

2686
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4275-4283.	7.0	916
2	Protein Kinase C β Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells. <i>Cancer Research</i> , 2004, 64, 5693-5701.	0.9	98
3	Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 10961.	3.3	63
4	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. <i>ESMO Open</i> , 2019, 4, e000531.	4.5	60
5	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). <i>Lung Cancer</i> , 2020, 143, 27-35.	2.0	42
6	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 765-774.	2.5	35
7	Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4205-4220.	7.0	29
8	Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma. <i>Anticancer Research</i> , 2016, 36, 1497-506.	1.1	29
9	EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. <i>Medical Oncology</i> , 2015, 32, 205.	2.5	27
10	Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients. <i>Oncology</i> , 2019, 96, 125-131.	1.9	22
11	Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 3425-31.	1.1	22
12	Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab. <i>Scientific Reports</i> , 2017, 7, 18027.	3.3	21
13	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	4.1	21
14	Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1613-1621.	2.5	18
15	An unbiased in vitro screen for activating epidermal growth factor receptor mutations. <i>Journal of Biological Chemistry</i> , 2019, 294, 9377-9389.	3.4	17
16	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. <i>JMIR Formative Research</i> , 2020, 4, e17898.	1.4	17
17	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 205.	3.0	15
18	Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage. <i>International Journal of Oncology</i> , 2015, 47, 1103-1110.	3.3	14

#	ARTICLE	IF	CITATIONS
19	Association of diagnostic delays to survival in lung cancer: single center experience. <i>Acta Oncologica</i> , 2019, 58, 1056-1061.	1.8	12
20	Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. <i>Oncotarget</i> , 2014, 5, 9295-9307.	1.8	12
21	The impact of severe mental illness on lung cancer mortality of patients with lung cancer in Finland in 1990â€“2013: a register-based cohort study. <i>European Journal of Cancer</i> , 2019, 118, 105-111.	2.8	11
22	Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. <i>ESMO Open</i> , 2017, 2, e000202.	4.5	10
23	A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. <i>International Journal of Cancer</i> , 2012, 131, 970-979.	5.1	9
24	Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study. <i>ESMO Open</i> , 2020, 5, e000864.	4.5	9
25	Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2153-2160.	2.5	8
26	Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results. <i>Journal of Clinical Oncology</i> , 2020, 38, 3097-3097.	1.6	7
27	HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC. <i>International Journal of Oncology</i> , 2017, 51, 599-606.	3.3	5
28	Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. <i>Acta Oncologica</i> , 2020, 59, 310-314.	1.8	5
29	Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1563.	2.5	4
30	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. <i>Cancers</i> , 2022, 14, 2276.	3.7	4
31	Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 443-450.	2.5	3
32	Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib. <i>Journal of Clinical Oncology</i> , 2018, 36, e21026-e21026.	1.6	2
33	Trends in treatment of non-small cell lung cancer in Finland 2014â€“2019. <i>Acta Oncologica</i> , 2022, 61, 641-648.	1.8	2
34	Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device. <i>Cancer Reports</i> , 0, , .	1.4	2
35	Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study. <i>Acta Oncologica</i> , 2021, 60, 1100-1105.	1.8	1
36	Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007â€“2018. <i>Melanoma Research</i> , 2021, 31, 456-463.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2nd line osimertinib.. Journal of Clinical Oncology, 2019, 37, e20544-e20544.	1.6	0